Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007

NCT00660881 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00660881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00660881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
December 31, 2011
Enrollment
210 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus